ClinicalTrials.gg
Not yet recruitingNCT06894953AMPERUpdated Mar 25, 2025

AMPER Proof of Concept Study

An interventional study of Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER) and Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER) in Alzheimer's Dementia (AD), sponsored by University of Strathclyde. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by University of Strathclyde · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 178 studies in Dementia with a site in United Kingdom — 39 open to participants now, 58 under way, 12 of them phase 3. Dementia · United Kingdom.

Planned enrollment
100th of 124
40 · median 196
Started
2025
with 13 others
No phase
56 of 178
7 open now
Primary completion
2026-02
later than 15 of 57 live
Registered
158th of 178
by date

Among the 178 studies in Dementia with a site in United Kingdom, this one is the 100th largest by planned enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 56 with no phase, reaches primary completion later than 15 of the 57 other live ones, and was the 158th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

39 of the 178 studies in Dementia with a site in United Kingdom are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies in Dementia with a site in United Kingdom, or all of them as a file.
02

Study summary

The AMPER (Agent-based Memory Prosthesis to Encourage Reminiscing) system has been built to help people with Alzheimer's disease by improving their memory recall and quality of life. Alzheimer's often leads to the loss of autobiographical memories, which can affect a person's sense of identity. AMPER seeks to address this by creating a digital memory aid that uses an engaging, animated character on a tablet to help individuals with Alzheimer's reminisce about their past. By presenting personally relevant stories, images, audio, and videos, the character helps trigger memories and encourages interaction with caregivers.

This is proof of concept study using a randomised controlled trial methodology. Twenty participants will be randomised to the control and 20 randomised to the intervention condition. The intervention group will use a personalised version of the AMPER app with tailored content and the control group will use a non-personalised version without specific adaptations. Over 12 weeks, participants will use the app at home with their caregivers. Researchers will measure changes in their memory and cognitive abilities before and after these 12 weeks.

The primary goal is to see if personalised reminiscence improves the perceived quality of the reminiscence experience and autobiographical memory ability compared to the same app with a non-personalised approach. This will be measured using a combination of automatically gathered app use data and weekly caregiver feedback. Secondary goals are to investigate any difference between participants in the intervention and control condition in their technology acceptance, quality of life, self-esteem, everyday functioning and cognitive ability.

Feedback from this research will help refine AMPER and inform future studies, with the ultimate goal of creating a widely accessible tool that supports memory and well-being in Alzheimer's patients. Table 1 provides a summary of the study.

03

Conditions studied

  • Alzheimer's Dementia (AD)

Browse trials for

Keywords

  • Azheimer's disease
  • Dementia
  • Reminiscence
  • Reminiscence technology
  • Assistive technology
  • Intelligent Virtual Agent
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of probable Alzheimer's disease of mild to moderate severity according to (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and NINCS-ADRAD (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) criteria.
  • Age 50 or older
  • Sensory (visual and auditory), language, and physical abilities adequate to perform assessments (corrective aids allowed).
  • ACE III score between 20 and 82 (inclusive) (or equivalent score on (between 14 and 24, based on Law et al., 20123 equivalence data) or MOCHA (between 14 and 24 (based on Pendleberry et al., 2011 equivalence data).
  • Having a caregiver or family member who can attend all visits, perform assessments, and supervise administration of study.

Exclusion criteria

Exclusion Criteria:

  • Medical records indicate AD patients with the visual variant or having colour vision deficits.
  • Medical records indicate a CT or MRI within 24 months prior to screening that indicates a diagnosis other than probable Alzheimer's disease.
  • Medical records indicate any significant neurological disease other than probable AD (e.g. Parkinson's disease, Huntington's disease, brain tumor, normal pressure hydrocephalus, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of stroke, or history of head injury requiring hospitalization).
  • On review of medical records, no abnormal findings on previous physical examination, medical history, or clinical laboratory results that would indicate an alternative diagnosis.
  • Current history of major psychiatric disorder (e.g. Major depression) (as indicated on medical records)
  • History of substance misuse (as indicated on medical records).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Personalised AMPER

    AMPER app will be provided on a tablet, used with a caregiver in the participant's home for 12 weeks, at least twice a week AND the app will cater topic 'stories' (content) to the persons pre-stated preferences and provide content from the decades that correspond to the person's reminiscence 'bump' (when they were between 10 and 30 years old).

    Device: Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)

  • Active comparator
    Non-personalised AMPER

    AMPER app will be provided on a tablet, used with a caregiver in the participant's home for 12 weeks, at least twice a week. AND the app will provide random content not linked to persons preferences or age.

    Device: Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)

Interventions

  • DevicePersonalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)

    AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Personalised AMPER is personalised to preferences and age of the participant.

  • DeviceNon-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)

    AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Non-personliased AMPER is not personalised to preferences or age of the participant.

06

What researchers measure

Primary outcomes

  1. Quality of autobiographical memory during AMPER use

    We will analyse the richness of episodic and semantic details in the participant's recollections (which are audio recorded during the trial). This method will ensure a systematic evaluation of memory quality during interactions facilitated by the AMPER app. This rating procedure will use the methodology outlined by Levine and colleagues (2002) and will be scored using the semi-automated methodology outlined by Wardell and colleagues (2021).

    Time frame: From enrollment to the end of AMPER use at 12 weeks

  2. Autobiographical Memory ability (objectively rated)

    Objective rating of Autobiographical Memory ability using the Autobiographical Memory Interview (Kopelman et al., 1989)

    Time frame: Baseline (week 1) and follow up (week 14)

  3. Autobiographical Memory ability (subjectively rated)

    Autobiographical memory ability will be subjectively rated using the Autobiographical Recollection Test (ART), (Berntsen et al., 2019).

    Time frame: Baseline (week 1) and follow up (week 14)

  4. Autobiographical Memory ability (subjectively rated on SAM)

    Autobiographical memory ability will also be subjectively rated using the survey of Autobiographical memory (SAM), (Palombo et al., 2012)

    Time frame: Baseline (week 1) and follow up (week 14)

Secondary outcomes

  1. Functional ability in tasks of everyday living

    Instrumental Activities of Daily Living (IADL), (Lawton \& Brody, 1969)

    Time frame: Baseline (week 1) and follow up (week 14)

  2. Quality of life for the individual with Alzheimer's disease (subjective)

    Quality of life Alzheimer's Disease (Logsdon et al., 1999)

    Time frame: Baseline (week 1) and follow up (week 14)

  3. Level of Depression experienced by the person with AD (subjective)

    Geriatric Depression Scale (GDS), (Yesavage et al., 1982),

    Time frame: Baseline (week 1) and follow up (week 14)

  4. Cognitive ability of the person with AD

    Addenbrooke's Cognitive Examination ACE-III (Mioshi et al., 2006)

    Time frame: Baseline (week 1) and follow up (week 14)

  5. Verbal learning ability for the person with AD

    Hopkins Verbal Learning Test (HVLT) (Benedict et al., 1998)

    Time frame: Baseline (week 1) and follow up (week 14)

  6. Short term verbal memory for person with AD

    Digit Span forwards and backwards from the Wechsler Adult Intelligence Scale (4th edition), (Wechsler, 2008)

    Time frame: Baseline (week 1) and follow up (week 14)

  7. Executive functioning for person with AD

    Trail Making Test (Reitan, \& Wolfson, 1985)

    Time frame: Baseline (week 1) and follow up (week 14)

  8. Modified Hachinski Ischemia Scale score for person with AD

    Modified Hachinski Ischemia Scale (mHIS) (Hachinski et al., 2012)

    Time frame: Baseline (week 1) and follow up (week 14)

  9. Self-esteem for the person with AD

    The Rosenberg Self Esteem scale (Rosenberg, 1965)

    Time frame: Baseline (week 1) and follow up (week 14)

  10. Technology acceptance for person with AD

    The ALMERE questionnaire (Heerink et al., 2010).

    Time frame: Baseline (week 1) and follow up (week 14)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Feb 2026, 10 months later.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 10 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 25, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Feb 28, 2026
CompletionEst.
Feb 28, 2026
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06894953
Lead sponsor
University of Strathclyde
Responsible party
Matt Jamieson (Principal Investigator, University of Strathclyde) — Principal investigator
First posted
Mar 25, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Mar 25, 2025

Study contacts

Matthew Jamieson, PhD
Contact
matthew.jamieson@strath.ac.uk
+44 7717780272

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion